Common Contracts
1 similar Clinical Study Agreement contracts
CLINICAL STUDY AGREEMENT PROTOCOL: CL010_168 SITE: 352 XXXXXXXXXXX CHEMOCENTRYX, INC. 19-APRIL-2017 VERSION: 1.0COUNTRY: CZECH REPUBLIC SMLOUVA O KLINICKÉ STUDII PROTOKOL: CL010_168 PRACOVIŠTĚ: 352 XXXXXXXXXX CHEMOCENTRYX, INC. 19.DUBEN 2017 VERZE:...Clinical Study Agreement • May 4th, 2017
CLINICAL STUDY AGREEMENTThis clinical study agreement (“Agreement”), dated 19- April-2017 (the “Effective Date”), is entered into by and amongMedpace, Inc., with its head office at 5375 Medpace Way, Cincinnati, Ohio 45227, USA, represented by XXXXXXXXXX., Clinical Trial Manager ("Medpace”); andFakultni nemocnice Kralovske Vinohrady, with its head office at Srobarova 1150/50, 10034 Praha 10, Czech Republic, reference number KH 1/2017, cost center 21007, represented by XXXXXXXXXXXX, Director ("Institution”). Medpace and Institution are sometimes collectively referred to herein as parties (the “Parties”). WHEREAS, ChemoCentryx, Inc., (“Sponsor”) is sponsoring a clinical study on the compound CCX168, in conjunction with, OE Prednisone [Prednisone acis® 5mg and 20mg tablets] (collectively called the “Study Drug”), in accordance with Protocol No. CL010_168, titled “A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patie
